GPT-Rosalind Sparks CRO Sector Slump: Should Investors Buy the Dip or Exit Amid AI Drug R&D Impact?
TradingKey - On April 16, 2026, OpenAI released GPT-Rosalind, a large language model specifically designed for life sciences research. Initial users include pharmaceutical giant Amgen (AMGN), vaccine manufacturer Moderna (MRNA), and the Allen Institute. Following the announcement, the CRO sector saw a broad decline, with IQVIA Holdings (IQV) falling 3.5% and Charles River Laboratories (CRL) dropping 2.6%. Recursion Pharmaceuticals (RXRX) and Schrodinger (SDGR) both tumbled over 5% at one point.